DUBLIN - Alkermes plc (NASDAQ:ALKS), a global biopharmaceutical company, announced today the appointment of Nancy S. Lurker as an independent director to its Board of Directors. Ms. Lurker, with a wealth of experience in the healthcare sector, has held leadership roles across a range of pharmaceutical and biotechnology companies.
The CEO of Alkermes, Richard Pops, highlighted Ms. Lurker's extensive background in executive leadership, strategic planning, and product commercialization, noting her expertise will be valuable as the company aims to grow its product portfolio and launch new products. Ms. Lurker expressed her enthusiasm for joining the board and contributing to Alkermes' mission in the neuroscience field.
Nancy Lurker's career includes her most recent role as CEO of EyePoint Pharmaceuticals (NASDAQ:EYPT), Inc., where she served from 2016 until July 2023 before transitioning to Executive Vice Chair of the board. Her previous positions include President and CEO of PDI, Inc., Senior Vice President and Chief Marketing Officer of Novartis (SIX:NOVN) Pharmaceuticals Corporation, and various senior roles at companies like Pharmacia Corporation and Bristol-Myers Squibb Company (NYSE:BMY).
Beyond her executive roles, Ms. Lurker has served on the boards of multiple healthcare and pharmaceutical organizations, including EyePoint Pharmaceuticals, Altasciences, LLC, and the National Sanitation Foundation. Her academic qualifications include a B.S. in Biology and an M.B.A.
Alkermes, headquartered in Dublin, Ireland, focuses on developing treatments for neurological and psychiatric conditions. The company has a robust portfolio of commercial products and a pipeline of clinical and preclinical candidates.
The information regarding the appointment of Ms. Lurker and details about her professional background are based on a press release statement from Alkermes.
InvestingPro Insights
As Alkermes plc (NASDAQ:ALKS) welcomes Nancy S. Lurker to its Board of Directors, the company's financial health and market performance provide a backdrop to the strategic expertise she brings. With a market capitalization of approximately $4.84 billion, Alkermes stands out with a strong financial position. The company's valuation implies a robust free cash flow yield, an InvestingPro Tip that signals the potential for sustained corporate growth and shareholder value creation.
Alkermes has demonstrated impressive revenue growth over the last twelve months as of Q4 2023, with an increase of 49.61%, indicating a solid trajectory in its commercial operations. The company's gross profit margin stands at a high 84.79%, reflecting efficient cost management and a healthy bottom line. Moreover, with an adjusted P/E ratio of 9.17, Alkermes appears to be an attractive investment when considering earnings potential.
Another InvestingPro Tip highlights that Alkermes' cash flows can sufficiently cover its interest payments, and its liquid assets exceed short-term obligations, suggesting a strong liquidity position. This financial stability is crucial as the company continues to expand its product portfolio and launch new products, areas where Ms. Lurker's experience will be particularly valuable.
For investors interested in deeper analysis and more InvestingPro Tips, there are 6 additional tips available on https://www.investing.com/pro/ALKS. These insights can help investors make informed decisions, especially when considering the company's next earnings date on April 24, 2024. To access these insights, use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.